What is Mithra Pharmaceuticals Capex-to-Operating-Cash-Flow?
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Hence, Mithra Pharmaceuticals's Capex-to-Operating-Cash-Flow for the
six
months ended in Jun. 2023 was 0.39.
Mithra Pharmaceuticals Capex-to-Operating-Cash-Flow Historical Data
The historical data trend for Mithra Pharmaceuticals's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mithra Pharmaceuticals's Capex-to-Operating-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Mithra Pharmaceuticals's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mithra Pharmaceuticals's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mithra Pharmaceuticals's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Mithra Pharmaceuticals's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Mithra Pharmaceuticals Capex-to-Operating-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Mithra Pharmaceuticals's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Mithra Pharmaceuticals (CHIX:MITRAB) Business Description
Mithra Pharmaceuticals SA develops products for women's health with a particular focus on fertility, contraception, and menopause. It operates in three segments: Product Sales, Out-licensing, and Other. The company also develops and markets complex therapeutic solutions and offers partners a complete spectrum of research, development, and specialist manufacturing at its Mithra CDMO. Its geographical segments are Belgium, Europe and Outside Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHIX:MITRAB has been successfully added to your 